Background Small studies suggest peanut oral immunotherapy (OIT) might be eff ective in the treatment of peanut allergy. We aimed to establish the effi cacy of OIT for the desensitisation of children with allergy to peanuts.
Introduction
Allergy to peanuts is an increasingly common and important medical disorder, aff ecting 0·5-1·4% of children in high-income countries. 1, 2 Peanut allergy is the most common cause of severe and fatal allergic reactions related to food, it is diffi cult to identify people at highest risk, 3 and resolution is uncommon. 4 Quality of life is reduced because of the likelihood of anaphylaxis, causing constant fear over food choices. 5, 6 Despite present management, families have poor knowledge of how to avoid and treat food allergy emergencies. 7 Accidental reactions are common, with annual incidences of 14-55%. [8] [9] [10] Therefore, there is a need for a disease-modifying therapy. Immunotherapy is an established treatment for inhalant allergies 11, 12 and insect-venom anaphylaxis. 13 Early studies of subcutaneous immunotherapy for peanut allergy were associated with severe adverse reactions, possibly due to the route of administration. 14 The oral route might be associated with greater safety, and has been studied in egg and milk allergy. 15, 16 There is a need for systematic study of oral immunotherapy (OIT) for the treatment peanut allergy. Therefore, after a phase 1 study that showed good tolerability, 17, 18 our aim was to establish the effi cacy of OIT for the desensitisation of children with allergy to peanuts.
Method Participants
Between January, 2010, and March, 2013, we did a singlecentre phase 2 randomised controlled two-phase trial at the NIHR/Wellcome Trust Cambridge Clinical Research Facility (Cambridge, UK). During the fi rst phase the active group underwent 26 weeks of peanut OIT, and the control group underwent 26 weeks of standard care (peanut avoidance). At the end of the fi rst phase (26 weeks) all participants were assessed for peanut allergy by double-blind placebo-controlled food challenge (DBPCFC). During the second phase, participants in the control group still allergic to peanuts were off ered peanut OIT, with a subsequent further DBPCFC.
Participants were recruited both locally (allergy clinic) and nationally (through national patient support group Anaphylaxis Campaign). Eligible participants were aged 7-16 years with an immediate hypersensitivity reaction after peanut ingestion, positive skin prick test to peanut (extract ALK-Abello, Hørsholm, Denmark) defi ned by weal of 3 mm or larger in the presence of a negative saline and positive histamine control, and positive DBPCFC. 19 We excluded participants if they had a major chronic illness (except for eczema, rhinitis, or asthma) since this was an immunomodulatory therapy, if the care provider or present household member had suspected or diagnosed allergy to peanuts, or if there was an unwillingness or inability to comply with study procedures. We did not exclude participants who had a previous life-threatening reaction, tree-nut allergy, or a history of severe asthma.
The Cambridge Central Ethics Committee approved the study (09/H0308/154) and the guardian of each participant gave written informed consent. Children of an appropriate age were encouraged to provide their own assent. The University of Cambridge and Cambridge University Hospitals NHS Trust (RD authorisation A091686) jointly sponsored the study. 
Randomisation and masking
Participants were randomly assigned (1:1) via an audited online system (Randomizer, Medical University of Graz, Austria) to receive either the active therapy or the control intervention. Minimisation was used to reduce imbalance of baseline covariates, with a random element using a weighting probability of 0·8. Factors were sex, age, challenge threshold, peanut specifi c serum IgE, severity from history, and presence of asthma or other food allergy. Group allocation was not masked.
Procedures
The active intervention (OIT) was given in daily doses of characterised peanut fl our (light roast fl our; Golden Peanut Company, Alphretta, GA, USA). First, there was a gradual updosing phase with 2 week increments to protein doses of 800 mg/day, and subsequently a maintenance period where the highest tolerated dose (with a target of 800 mg/ day) was taken daily to complete a total of 26 weeks OIT. We devised a novel updosing regime, diff erent from other published protocols (patent pending): doses were 2 mg, 5 mg, 12·5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 800 mg of peanut protein. 18 The rationale for choosing a daily maintenance dose of 800 mg was on the basis of the highest amount of peanut protein used in the pilot study that participants were able to ingest on an ongoing daily basis, which was also associated with a suggestion of effi cacy. Peanut protein was presented as a fi nely ground defatted powder that was mixed into food before ingestion. Dose increments took place in the NIHR/Wellcome Trust Clinical Research Facility and participants were observed for 2 h. The same dose was then given at home daily for 2-3 weeks. Participants were asked to take their dose with food and instructed not to exercise for 2 h after taking a dose. Participants were asked to complete symptom diaries and were provided with adrenaline autoinjectors. At the end of the study participants were encouraged to continue daily consumption of 800 mg peanut protein.
Outcomes
The primary outcome was the proportion of desensitised participants in each group at the end of the fi rst phase. Desensitisation was defi ned as no reaction during peanut DBPCFC with a cumulative dose of 1400 mg peanut protein. The primary outcome was assessed for all participants together and also by recruitment group (local or national). Secondary outcomes were the proportion of participants who tolerated daily ingestion of 800 mg protein (equivalent to fi ve peanuts) up to 26 weeks; the proportion of the control group who were desensitised or tolerated daily ingestion of 800 mg protein during the second phase; the fold and absolute increase in threshold (maximum tolerated peanut protein in mg) after OIT-defi ned as no observed adverse eff ect level (NOAEL; highest dose of peanut protein tolerated in mg protein during challenge or immunotherapy); the change in quality-of-life score;
the number and type of adverse events; the change in immunological outcomes (basophil area under curve of CD63% and mean fl uorescent intensity [MFI], peanut specifi c IgE, total IgE, and skin prick test weal diameter).
All peanut challenges were done as DBPCFCs in accordance with best practice, 19 using separate active and placebo phases and masked with the validated EuroPrevall dessert food carrier recipe (range of doses from 5, 50, 100, 300, and 1000 mg peanut protein). 20 We chose a cumulative challenge dose equivalent to roughly ten peanuts to show desensitisation to an amount of peanut that we judged unlikely to be encountered accidentally after OIT. Random number lists established the order of DBPCFC placebo and active arms. All study personnel were masked to the challenge assignment except the scientist who prepared the challenge material; they had no interaction with the participant or study team.
Quality of life was measured by a disease-specifi c questionnaire, the Food Allergy Quality of Life-Parent Form (FAQLQ-PF), available for 0-12 years. 21 Hence this questionnaire was only off ered to families with a child aged 7-12 years. The questionnaire was scored on a sixpoint scale, averaged over three areas with equal weighting: emotional impact, food anxiety, and social and dietary limitation. Scores were obtained from baseline and the end of each phase.
Flow cytometric analysis (fl uorescence-activated cell sorting) of patient samples was done on whole-blood specimens to quantify the proportion and MFI of CD63 basophils. Skin prick tests were done with standardised peanut extract from ALK-Abello, (Hørsholm, Denmark) and a single point lancet. Peanut specifi c IgE was measured with the ImmunoCap system (Thermo Scientifi c, Waltham, MA, USA). Measurements were made at baseline and after each phase.
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Statistical analyses
All analyses were planned prospectively and detailed in a statistical analysis plan. Fisher's exact test was used to compare the proportion of participants with desensitisation to peanut after 6 months between the active and control group at the end of the fi rst phase. Exact unconditional confi dence limits for the absolute risk diff erence were calculated. Secondary analyses tested for treatment diff erences with Fisher's exact test (proportion response to treatment in active group and control group at end of the second phase), Wilcoxon signed rank tests (absolute and fold change in threshold), and Mann-Whitney U test (diff erence between groups in quality-of-life scores, basophil area under curve of CD63% and MFI, peanut-specifi c IgE, and skin prick test weal diameter).
Tobit regression 22 was used in preference to linear regression, because it is better suited to analysis of censored dependent variables. We expected a large number of NOAEL values to be right censored at 1400 mg, as successfully desensitised participants would not react to this top dose during challenge. Estimates were provided for treatment on 6 month NOAEL adjusted for baseline covariates. All statistical tests described use a two-sided 5% signifi cance level. Intention-to-treat analysis was done on the full analysis population that included all participants who were randomised and participated in at least one post-baseline assessment (DBPCFC).
Sample size was based on Fisher's exact test with 90% power and 5% signifi cance (two-sided). A sample size of 49 in each group is suffi cient to detect proportions of participants with desensitisation to peanut of 0·64 and 0·30 in the active and control groups respectively at the end of the fi rst phase. Allowing for 5% dropout increased the sample size to 52 participants in each group and 104 overall. Based on the above we would expect 35 waiting list group participants to proceed to the active intervention in the second phase.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. We enrolled 104 children, aged 7-16 years (median 12·4 years). The baseline characteristics of the participants are listed in the appendix. Five children did not react during their baseline peanut challenge. Therefore 99 children were randomly assigned to the study groups: 49 active and 50 control (fi gure 1). One child discontinued and fi ve withdrew from the active group during the fi rst phase. Four further participants were excluded from the primary analysis because they had not reached the target See Online for appendix maintenance OIT dose at 6 months. In the control group, four children withdrew and one discontinued during the fi rst phase. There was a signifi cant diff erence between the proportions of participants who had no reaction to 1400 mg peanut protein during DBPCFC at the end of the fi rst phase in the active (24 of 39 participants; 62%, 95% CI 45-78%) compared with the control group (0 of 46; 0%, 95% CI 0-9·1; p<0·001; table 1). The absolute risk diff erence was estimated as 62% with a conservative 95% CI of 43-77. There was no signifi cant diff erence in primary outcome between locally and nationally recruited participants (data not shown).
Results
84% (95% CI 70-93) of the active group at the end of the fi rst phase, and 91% (79-98) of the control group at the end of the second phase (after OIT) were able to tolerate daily ingestion of 800 mg protein for 26 weeks. There was a signifi cant increase in peanut NOAEL in the active group after the fi rst phase, with a median change in threshold of 25·5 times (p<0·001; table 1) compared with a small negative change in peanut threshold (NOAEL) in the control group during the fi rst phase (0·81, range 0·05-1·82; fi gure 2).
Quality-of-life scores assessed by the FAQLQ-PF instrument 21 were similar in active and control groups at baseline. Both groups showed a similar and clinically meaningful improvement (decrease) in quality of life scores after treatment (table 1) .
Immunological assessments showed a signifi cant small reduction in median skin prick test weal diameter and increase in peanut-specifi c IgE after 24 weeks OIT in the active group (appendix). Basophil stimulation test data were expressed as the area under the curve (AUC) of plots of MFI and proportion of CD63-positive cells against concentration of peanut protein. No signifi cant within-patient diff erences were identifi ed after treatment for AUC of MFI or proportion of CD63, although there was a reduction in MFI and proportion of CD63 at lower peanut concentrations after OIT (fi gure 3).
Tobit regression suggested several baseline covariates could aff ect the fi nal NOAEL (table 2) . Baseline NOAEL, World Allergy Organization grade 2 reaction, and total IgE were also associated with higher post-OIT NOAEL. Age, family history, weight, and peanut-specifi c IgE were associated with lower fi nal NOAEL.
The number and nature of adverse events was similar in both groups after treatment. Most events were mild with oral itching being the most common (occurring after 6·3% of all doses; table 3). Cutaneous events were uncommon, present after only 0·16% of doses. Wheezing occurred after 0·41% of doses in 22% of participants and was treated with inhaled β 2 agonists and oral antihistamines alone in all cases except for one participant who, additionally, self-administered intra muscular adrenaline on two occasions, with rapid resolution of his symptoms. There were no serious adverse reactions and no cardiovascular events.
Estimate (95% CI) p value
Oral immunotherapy 105·5 (67·73-164·40) <0·001
Quality of life 1·12 (0·89-1·42) 0·32 
Discussion
Daily doses of peanut OIT of up to 800 mg protein had a clinically meaningful eff ect, shown by a high incidence of desensitisation, large absolute and fold increases in threshold (NOAEL), and a signifi cant improvement in quality-of-life score; 84% of participants in fi rst phase and 91% in the second phase could tolerate daily ingestion roughly equivalent to fi ve peanuts per day. To our knowledge, our fi ndings provide the fi rst well controlled and accurate estimate of the eff ect size, benefi ts, and risks of desensitisation with peanut OIT (panel). Raising the reactive threshold for patients is a key outcome of this treatment. Without OIT, patient ability to avoid hidden peanuts is based on previous experience and inconsistent labelling and advice from food providers. 3, [24] [25] [26] Consequently, accidental reactions often happen (14-55% per year [8] [9] [10] ) and involve the use of health-care resources. Fear of death and severe reactions drives down quality of life. 5, 6 Peanut OIT raises the reactive threshold at least 25-times so that 84-91% of participants can tolerate daily ingestion of 800 mg protein. Furthermore, 54-62% of children can tolerate a challenge with 1400 mg protein, roughly equivalent to ten peanuts. We showed previously that two-thirds of individuals who can tolerate 1400 mg could also tolerate 6000 mg protein (equivalent to 38 peanuts). Those who could not had only mild reactions. 18 These calculations are based on an average peanut containing 160 mg protein, although variation occurs up to 260 mg. This treatment therefore allows participants to eat large quantities of peanuts, above the levels present in contaminated snacks and meals, allowing them to eat more freely and enjoy a reduction in social restrictions. Consequently, our study confi rms an improvement in food-allergy specifi c quality of life, suggested by an earlier uncontrolled study of peanut OIT. 27 Quality of life was measured on a validated disease-specifi c six-point scale 21 and the improvements evident in the active and control groups after intervention (-1·61, -1·41) are clinically meaningful, although participants were not masked to treatment allocation and this might have introduced bias.
Our fi ndings should be interpreted in the context of the study limitations. We did not mask treatment allocation. Instead we used a masked objective test to measure the primary outcome (ie, no reaction to peanut during DBPCFC). There was a small risk of bias as participants who knew they were receiving active treatment might have under-reported minor symptoms at the higher challenge doses, although these symptoms would have been uncommon and subjective. Additionally, during fi rst phase, ten participants did not undergo a post-OIT challenge because they had withdrawn or not reached the target maintenance OIT dose at 6 months. It is probable that in the fi rst phase the true response rate is lower than estimated; however, in the second phase, where there were few dropouts, we still noted a large eff ect. A very conservative sensitivity analysis was done in which all the unobserved participants in the active group were imputed as not desensitised and all the unobserved participants in the control group were imputed as desensitised. The analysis gave a risk diff erence of 0·41 (95% CI 0·21-0·58), which supports the conclusions of our main analysis.
Since, to our knowledge, this is the fi rst study of its type, our fi ndings are relevant to the population studied, but will need confi rmation in other subgroups of patients. Because of the signifi cant risks involved, OIT should be restricted to specialist centres.
We studied desensitisation over a 6 month period, rather than tolerance after cessation of treatment, because stopping OIT after a median of 9 months has been shown to lead to loss of desensitisation. 28 It is probable that long-term peanut protein ingestion will be needed to provide continued protection from accidental exposure, perhaps for several years. This view is supported by immunological investigation; during peanut OIT, we showed evidence of basophil and mast-cell desensitisation and other groups have shown a gradual change in peanut-specifi c T-cell-
Panel: Research in context

Systematic review
We searched PubMed and the Cochrane database for English language publications with the MeSH terms "peanut oral immunotherapy", "peanut desensitization", and "peanut tolerance". Date limits for our search were from January, 1980, to August, 2013. A recent systematic review of studies of peanut oral immunotherapy (OIT) identifi ed a single small randomised controlled study in 28 children. 23 It suggested a positive eff ect of peanut OIT but was not powered to estimate effi cacy. Interpretation of published studies has also been hampered by small size, exclusion of severely allergic children, and failure to confi rm allergic status on enrolment by food challenge.
Interpretation
To our knowledge, we did the fi rst phase 2 study appropriately powered to derive an accurate estimate of the eff ect size of the treatment in children aged 7-15 years. By contrast with other studies, we assessed a representative UK population including children with severe reactions, with allergy confi rmed by DBPCFC. 84% and 91% of participants could tolerate the equivalent of fi ve peanuts per day, and a high rate of desensitisation (ability to tolerate the equivalent of roughly ten peanuts) was shown. There was a substantial eff ect size, and improvement in quality of life with a good safety profi le. Tolerance after cessation of OIT was not assessed. Our data apply to the population studied and the doses employed, and there is a need for replication and expansion of populations studied. This study shows that peanut immunotherapy is an eff ective and well tolerated treatment in this age group.
surface markers from Th2 to Th1 phenotype. 29 Longlived terminally diff erentiated IgE secreting plasma cells survive in the bone marrow in this environment for years, consequently, peanut specifi c IgE levels persist for several years after starting OIT, despite apparent clinical desensitisation. 29 Unsurprisingly there were many more allergic events during active treatment than during periods of peanut avoidance. The safety data in this trial show most adverse events were mild and due to gastrointestinal symptoms (eg, oral itching), as expected from the route of administration. Skin reactions were uncommon (urticaria after 0·16% of doses). Reactions involving wheezing occurred after 0·41% of doses, or roughly one fi fth of participants. Although wheezing could be taken as a sign of a more severe reaction, in all but one participant it was mild and responded to standard doses of inhaled bronchodilator drugs. One participant selfadministered adrenaline at home with good eff ect on two occasions for wheezing after his peanut OIT doses-he was withdrawn from the study. No participants had hypotension.
We previously devised a new regimen 18 with a standard starting dose for all participants, because our pilot study 17 showed that tailoring the starting dose to individual thresholds commonly resulted in adverse events, even at low doses. This regime is therefore better tolerated and an improvement. From the limited data available in published work it is apparent that the speed of the updosing schedule has a greater negative eff ect on safety and effi cacy than the size of the maintenance dose, with semi-rush regimens showing less effi cacy and more common reactions. 28, 29 We therefore used a gradual updosing regimen.
Prognostic factors were explored with Tobit regression. 22 Treatment with OIT was, unsurprisingly, the most infl uential positive factor. Serum peanut-specifi c IgE, age, and family history were also associated with a negative eff ect on NOAEL (weight had a weak eff ect). These are all prognostic factors that one would intuitively think would make immunotherapy more diffi cult, and need further study.
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